Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model

Behavioural Brain Research

Volumn 229, Issue 1, 2012, Pages 244-249

  Heulens, Inge ^a   D'Hulst, Charlotte ^a,e   Van Dam, Debby ^b   De Deyn, Peter P ^b,c,d   Kooy, R Frank ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Audiogenic seizures; Fragile X syndrome; GABA A receptor; Ganaxolone; Mouse behaviour; Neuroactive steroids

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DIAZEPAM; GANAXOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RECEPTOR BINDING; FRAGILE X SYNDROME; GABAERGIC SYSTEM; GENE INACTIVATION; MALE; MAZE TEST; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR SENSITIVITY; ROTAROD TEST; SEDATION; TRANQUILIZING ACTIVITY; WILD TYPE;

ANALYSIS OF VARIANCE; ANESTHETICS; ANIMALS; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, REFLEX; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GABA MODULATORS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PREGNANEDIONES; PSYCHOMOTOR PERFORMANCE; ROTAROD PERFORMANCE TEST;

EID: 84856578911     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.031     Document Type: Article

References (44)

1. Hagerman R.J. Physical and behavioral phenotype. Fragile X syndrome: diagnosis, treatment and research 2002, 3-109. Johns Hopkins University Press, Baltimore, MA. R.J. Hagerman, P.J. Hagerman (Eds.).
2. Musumeci S.A., Hagerman R.J., Ferri R., Bosco P., Dalla Bernardina B., Tassinari C.A., et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999, 40:1092-1099.
3. Verkerk A.J.M.H., Pieretti M., Sutcliffe J.S., Fu Y-H., Kuhl D.P.A., Pizzuti A., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
4. Pieretti M., Zhang F., Fu Y-H., Warren S.T., Oostra B.A., Caskey C.T., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66:817-822.
5. Eberhart D.E., Malter H.E., Feng Y., Warren S.T. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 1996, 5:1083-1091.
6. Tamanini F., Meijer N., Verheij C., Willems P.J., Galjaard H., Oostra B.A., et al. FMRP is associated to the ribosomes via RNA. Hum Mol Genet 1996, 5:809-813.
7. Khandjian E.W., Corbin F., Woerly S., Rousseau F. The fragile X mental retardation protein is associated with ribosomes. Nat Genet 1996, 12:91-93.
8. Laggerbauer B., Ostareck D., Keidel E.M., Ostareck-Lederer A., Fischer U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 2001, 10:329-338.
9. Zalfa F., Eleuteri B., Dickson K.S., Mercaldo V., De Rubeis S., di Penta A., et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 2007, 10:578-587.
10. A receptor in fragile X syndrome. Brain Res 2006, 1121:238-245.
11. D'Hulst C., Heulens I., Brouwer J.R., Willemsen R., De Geest N., Reeve S.P., et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res 2009, 1253:176-183.
12. A receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 2005, 377:141-146.
13. Curia G., Papouin T., Seguela P., Avoli M. Downregulation of tonic GABAergic Inhibition in a mouse model of fragile X syndrome. Cereb Cortex 2009, 19:1515-1520.
14. D'Antuono M., Merlo D., Avoli M. Involvement of cholinergic and gabaergic systems in the fragile X knockout mice. Neuroscience 2003, 119:9-13.
15. Centonze D., Rossi S., Mercaldo V., Napoli I., Ciotti M.T., Chiara V.D., et al. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry 2008, 63:963-973.
16. D'Hulst C., Kooy R.F. The GABA(A) receptor: a novel target for treatment of fragile X. Trends Neurosci 2007, 30:425-431.
17. Sieghart W., Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2002, 2:795-816.
18. Nohria V., Giller E. Ganaxolone. Neurotherapeutics 2007, 4:102-105.
19. Mihalek R.M., Banerjee P.K., Korpi E.R., Quinlan J.J., Firestone L.L., Mi Z-P., et al. Attenuated sensitivity to neuroactive steroids in γ-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 1999, 96:12905-12910.
20. A receptor by depressant barbiturates and pregnane steroids. Br J Pharmacol 1988, 94:1257-1269.
21. Lambert J.J., Belelli D., Hill-Venning C., Neurosteroids Peters J.A. GABAA receptor function. Trends Pharmacol Sci 1995, 16:295-303.
22. Carter R.B., Wood P.L., Wieland S., Hawkinson J.E., Belelli D., Lambert J.J., et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 1997, 280:1284-1295.
23. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
24. Treiman D.M. GABAergic mechanisms in epilepsy. Epilepsia 2001, 42(Suppl. 3):8-12.
25. Peier A.M., McIlwain K.L., Kenneson A., Warren S.T., Paylor R., Nelson D.L. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 2000, 9:1145-1159.
26. Thomas A.M., Bui N., Graham D., Perkins J.R., Yuva-Paylor L.A., Paylor R. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav Brain Res 2011, 223:310-321.
27. Thomas A.M., Bui N., Perkins J.R., Yuva-Paylor L.A., Paylor R., Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 2012, 219:47-58.
28. Nielsen D.M., Derber W.J., McClellan D.A., Crnic L.S. Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 2002, 927:8-17.
29. Yan Q.J., Asafo-Adjei P.K., Arnold H.M., Brown R.E., Bauchwitz R.P. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 2004, 3:337-359.
30. Restivo L., Ferrari F., Passino E., Sgobio C., Bock J., Oostra B.A., et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci USA 2005, 102:11557-11562.
31. Spencer C.M., Alekseyenko O., Serysheva E., Yuva-Paylor L.A., Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 2005, 4:420-430.
32. Spencer C.M., Graham D.F., Yuva-Paylor L.A., Nelson D.L., Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci 2008, 122:710-715.
33. Yuskaitis C.J., Mines M.A., King M.K., Sweatt J.D., Miller C.A., Jope R.S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 2010, 79:632-646.
34. Liu Z.H., Chuang D.M., Smith C.B. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 2011, 14:618-630.
35. Veeraragavan S., Bui N., Perkins J.R., Yuva-Paylor L.A., Carpenter R.L., Paylor R. Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology (Berl) 2011, 217:143-151.
36. Van Dam D., D'Hooge R., Hauben U., Reyniers E., Gantois I., Bakker C.E., et al. Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav Brain Res 2000, 117:127-136.
37. Mineur Y.S., Sluyter F., de Wit S., Oostra B.A., Crusio W.E. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 2002, 12:39-46.
38. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007, 2:322-328.
39. De Sarro G., Gitto R., Rizzo M., Zappia M., De Sarro A. 1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice. Gen Pharmacol 1996, 27:935-941.
40. Fradley R.L., Guscott M.R., Bull S., Hallett D.J., Goodacre S.C., Wafford K.A., et al. Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. J Psychopharmacol (Oxford, England) 2007, 21:384-391.
41. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006, 69:273-294.
42. Reddy D.S., Rogawski M.A. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6:392-401.
43. Chang S., Bray S.M., Li Z., Zarnescu D.C., He C., Jin P., et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nature Chem Biol 2008, 4:256-263.
44. Reddy D.S. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009, 85:1-30.